While the epidermal growth factor (EGF) and vascular endothelial growth factor (VEGF) pathways have been successfully targeted for therapeutic purposes in advanced CRC, the prognostic and therapeutic role of other crucial signaling cascades frequently altered in CRC, such as the phosphatidylinositol 3-kinase (PI3K) pathway, remain elusive (2). The gene discussed is EGF; the disease is colorectal carcinoma.